|   Size |   Grade | Involved lymph node | PR status | HER-2 status | Ki-67 status |   LVI |   MVD | Loco-regional treatment | Systemic treatment |
---|---|---|---|---|---|---|---|---|---|---|
 | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) |
Age (≤50/>50 years) | 0.241 | 0.908 | 0.242 | 0.002 | 0.154 | 0.772 | 0.826 | 0.347 | 0.282 | 0.059 |
Size (≤20/21-50/>50 mm) |  | 0.181 | 0.004 | 0.131 | 0.343 | 0.085 | 0.011 | 0.106 | 0.042 | 0.151 |
Grade (I/II/III) | Â | Â | 0.127 | 0.049 | 0.730 | 0.586 | 0.042 | 0.586 | 0.980 | 0.164 |
Involved lymph node (0/1-3/>3) | Â | Â | Â | 0.166 | 0.058 | 0.392 | <0.001 | 0.068 | 0.013 | 0.118 |
Progesterone –receptor status (PR-/PR+) |  |  |  |  | 0.769 | 0.985 | 0.111 | 0.191 | 0.093 | 0.272 |
HER-2 status (HER-2 -/HER-2+) | Â | Â | Â | Â | Â | 0.949 | 0.001 | 0.340 | 0.068 | 0.292 |
Ki-67 proliferative activity (Low Ki-67/High Ki-67) | Â | Â | Â | Â | Â | Â | 0.739 | 0.651 | 0.256 | 0.335 |
LVI (Absent/Present) | Â | Â | Â | Â | Â | Â | Â | 0.414 | 0.054 | 0.563 |
MVD (tertiles 1, 2, 3) | Â | Â | Â | Â | Â | Â | Â | Â | 0.020 | 0.944 |
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) |  |  |  |  |  |  |  |  |  | 0.432 |